The matrix below maps each gut-derived metabolite class to its established or hypothesized cardiovascular mechanisms, using only evidence from the supplied sources. Note an important asymmetry: the records cover TMAO and SCFAs well, but no supplied source contains quantitative data on bile acids or aryl-hydrocarbon receptor ligands (AAA derivatives such as indoxyl sulfate), so those rows are marked as gaps rather than filled with memory-based claims.
| Metabolite | Origin / Pathway | CVD Mechanism(s) | Key Human Evidence | Evidence Strength |
|---|---|---|---|---|
| TMAO | Dietary choline/carnitine/phosphatidylcholine β microbial TMA lyases (cntA/B, cutC/D, yeaW/X) β TMA β hepatic FMO3 oxidation | Platelet hyperreactivity via enhanced IP3-mediated Ca2+ release; pro-thrombotic state; MAPK (p38/ERK/JNK), NF-ΞΊB, NLRP3 inflammasome activation; ROS; reduced NO bioavailability; endothelial dysfunction | nβ4,007 cohort: highest vs lowest TMAO quartile HR 1.64 for incident MI/stroke over 3 years (p<0.001); red-meat crossover diet (n=113) raised TMAO vs white/non-meat | Strong (mechanistic + cohort) |
| TMAO precursors (choline, carnitine, betaine) | Dietary; plasma choline (r=0.28, p<0.0001) and carnitine (r=0.21, p=0.0002) correlate with plasma TMAO in healthy adults | Substrate supply for microbial TMA production; fish is a major direct TMAO source, complicating biomarker interpretation | KarMeN study (n=297): diet explained only 0.7β24.8% of TMAO variance; fish consumers showed stronger choline-TMAO correlation (r=0.52) | Moderate (cross-sectional) |
| SCFAs (propionate, butyrate, valerate) | Microbial fiber fermentation (e.g., inulin increases fecal propionic, butyric, valeric acids) | Suppression of pro-inflammatory M1 macrophages (βiNOS, βTNF-Ξ±) and promotion of anti-inflammatory M2 macrophages (βArg-1, βIL-10, βCD206) via attenuation of TLR4-MyD88-NF-ΞΊB signaling | Mouse ALD model (n=60): all SCFAβmacrophage correlations significant (pβ€0.0043); in vitro propionate/butyrate/valerate shifted M1/M2 polarization (pβ€0.0191). No supplied human CVD outcome data | Moderate (preclinical only) |
| Bile acids | Hepatic/ microbial conversion; FXR is the key nuclear receptor | Supplied records show only FXR hepatic mRNA trends in a porcine diet model (near-significant, p=0.06) β no CVD mechanism data | Gap: no quantitative CVD evidence in supplied sources | Insufficient |
| AAA derivatives (e.g., indoxyl sulfate) | Tryptophan fermentation products | One completed trial (NCT06877585) examined fecal microbiota/metabolite associations with indoxyl sulfate; results not in supplied records | Gap: no quantitative CVD evidence in supplied sources | Insufficient |
Critical caveats: TMAOβthrombosis human data are observational with residual confounding possible; the platelet receptor for TMAO remains unidentified; mouse TMAO doses (i.p., achieving ~93 mM plasma) may exceed physiological human exposure; both lead TMAO authors hold diagnostic patents and industry royalties, a disclosure worth weighing; SCFA macrophage findings derive from female mice and RAW264.7 cells with unknown human translation; microbiotaβTMAO taxon correlations in the porcine model were uncorrected for multiple testing. In the KarMeN quartiles, higher TMAO tracked older age (40β57 years, p<0.0001), lower GFR (119.6β104.3), and higher blood pressure β confounders that themselves associate with CVD.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.